追求更好的恶性肿瘤治疗选项，基于金属的配合物持续展现出极具吸引力的化疗药物潜力，因为其可调性，新颖的机制和效力，如铂系药物所示。肿瘤的代谢特征使线粒体和其他代谢途径成为无机药物化学有益的治疗目标。对线粒体在肿瘤发生中作用的积累理解，激发了对靶向线粒体的金属配合物的研究，以克服耐药性，高效和选择性地抑制肿瘤生长。本文讨论了第三周期过渡金属的线粒体靶向药物的最新进展，旨在激发一个积极的研究领域，开发新的临床抗癌药物，并阐明新的作用机制。版权所有©2022 Elsevier Ltd.。保留所有权利。

In pursuit of better treatment options for malignant tumors, metal-based complexes continue to show promise as attractive chemotherapeutics due to tunability, novel mechanisms, and potency exemplified by platinum agents. The metabolic character of tumors renders the mitochondria and other metabolism pathways fruitful targets for medicinal inorganic chemistry. Cumulative understanding of the role of mitochondria in tumorigenesis has ignited research in mitochondrial targeting metal-based complexes to overcome resistance and inhibit tumor growth with high potency and selectivity. Here, we discuss recent progress made in third row transition metal-based mitochondrial targeting agents with the goal of stimulating an active field of research toward new clinical anticancer agents and the elucidation of novel mechanisms of action.Copyright © 2022 Elsevier Ltd. All rights reserved.